Tuesday, 23 Apr 2019

You are here

Statin Associated with an Increase in Inflammatory Myopathy

JAMA Internal Medicine reports that exposure to statin medications may be linked to histologically confirmed idiopathic inflammatory myositis.

A population-based, case-control study, using the South Australian Myositis Database, examined 221 patients with idiopathic inflammatory myositis (IIM) matched 1:3 with 662 controls. The 221 IIM cases had a mean age of 62.2 years, and 132 (59.7%) were female

Statin exposure at the time of IIM diagnosis was seen in 30.8% of the IIM patients  and 21.5% of controls (P = .005). There was a statistically significant 79% increased risk of idiopathic inflammatory myositis cases in those exposed to a statin drug  compared with controls (adjusted odds ratio, 1.79; 95% CI, 1.23-2.60; P = .001). 

The CDC estimates nearly 71% of adults with cardiovascular disease and 54% of adults with hypercholesterolemia use a cholesterol-lowering. While myalgias are common,  but myopathy occurs in less than 1% and rhabdomyolysis and necrotizing myositis are very rare.  A NEJM article has shown that autoantibodies against 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and is estimated to occur in approximately 2 or 3 of every 100,000 patients treated with statins.  

 

 

 

 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

EULAR 2019 Update to Lupus Management

The goal of SLE treatment is remission or low disease activity and flare prevention. Hydroxychloroquine is recommended in all patients with lupus, at a dose not exceeding 5 mg/kg real body weight. Glucocorticoids (GC) should be minimised to less than 7.5 mg/day (prednisone equivalent). Appropriate initiation of immunomodulatory agents (methotrexate, azathioprine, mycophenolate) can be tailored to the clinical scenarios and may allow for tapering or discontinuation of GC.

Mortality Risk Factors in Systemic Sclerosis

A French cohort study of 625 systemic sclerosis (SStc) patients has found a significantly increased mortality risk that can be predicted by common clinical variables.

In addition to a multicenter prospective study, investigators performed a metanalysis on SSc standarized mortality ratios (SMR) and hazard ratios of prognosis factors.

Better Tests Ahead in Lupus

The advent of "big data" and "-omics" technologies offers hope that clinicians will soon have better diagnostics for systemic lupus erythematosus, rheumatologists here were told.

GCA Relapse Risk High with Steroids

Prior to the introduction of tocilizumab to manage giant cell arteritis (GCA), glucocorticoids (GC) have been the mainstay of therapy, but has been limited by relapses in disease. A recent metanalysis shows that relapses occur in nearly half of patients and are related to the duration of therapy rather than the initial dose of GC.

A literature review found 34 studies (2,505 patients) from 8 RCTs of GCA patients only treated with GC.

Presenting Features of Early SLE

What clinical features best identify early systemic lupus erythematosus (SLE) patients from mimics?  A multicenter, multinational study aimed to evaluate manifestations at disease onset and to compare early SLE manifestations to those of diseases mimicking SLE.